Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy
Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) and Memo Therapeutics AG jointly announced a definitive share...
EPA: IPN
Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline
Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) and Kartos Therapeutics announced a definitive merger agreement under...
European Commission Grants Conditional Approval to Ipsen’s Ojemda (Tovorafenib) for Pediatric Low-Grade Glioma with BRAF Alterations
Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced on April 22, 2026, that the European Commission...
Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted...
Ipsen Launches BYLVAY in China for Rare Liver Disease
France‑based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the official commercial launch of its rare‑disease...
Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors
France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx...
Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China
France-based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the signing of a cooperation agreement with...
Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st
France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the appointment of Olivia Brown...
Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology
French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...
Ipsen’s Bylvay Receives NMPA Clearance for Treating Itching in PFIC Patients in China
France-based Ipsen (EPA: IPN) has announced that it has received marketing clearance from the National...
Ipsen S.A. Receives NMPA Green Light for Six-Month Diphereline Dosage in Central Precocious Puberty
Ipsen S.A. (EPA: IPN; OTCMKTS: IPSEY) has announced that it has received marketing approval from...
Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001
Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement...
Ipsen’s Somatuline Receives First Prescription in China for GEP-NETs Treatment
French biopharmaceutical company Ipsen (EPA: IPN; OTCMKTS: IPSEY) has announced that the first prescription of...
Ipsen Secures NMPA Approval for Somatuline in Advanced Neuroendocrine Tumors
Ipsen (EPA: IPN; OTCMKTS: IPSEY), a France-based biopharmaceutical company, has received new indication approval from...
Ipsen Secures FDA Approval for Onivyde Regimen as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma
Ipsen (EPA: IPN, OTCMKTS: IPSEY), the France-based biopharmaceutical company, has announced that the U.S. Food...